Lamivudine: Difference between revisions
Jump to navigation
Jump to search
imported>David E. Volk mNo edit summary |
imported>Caesar Schinas m (Bot: Replacing medical templates with CZMed) |
||
Line 37: | Line 37: | ||
== External links == | == External links == | ||
{{CZMed}} | |||
Revision as of 00:28, 3 June 2009
| |||||||
lamivudine | |||||||
| |||||||
Uses: | HIV/AIDS & Hep. B | ||||||
Properties: | cytosine-like RT inhibitor | ||||||
Hazards: | see drug interactions | ||||||
|
Lamivudine is a nucleotide-based reverse transcriptase inhibitor used to treat HIV/AIDS and hepatitis B virus. It is an analog of zalcitabine that competes, in the triphosphate form, for incorporation in viral DNA with cytosine triphosphate. Lacking a 3'-OH group, it terminates DNA chain elongation because the phosphodiester bond necessary for elongation cannot be made.
Its IUPAC name is 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one and it has chemical formula C8H11N3O3S, giving it a molecular mass of 229.2562 g/mol.
Brand names
single drug brand names
- 3TC
- Epivir
- Epivir-HBV
- Hepitec
- Heptovir
- Zeffix
brand mixtures
- Combivir (Lamivudine + Zidovudine)
- Kivexa (Abacavir (Abacavir Sulfate) + Lamivudine)
- Trizivir (Abacavir (Abacavir Sulfate) + Lamivudine + Zidovudine)
External links
The most up-to-date information about Lamivudine and other drugs can be found at the following sites.
- Lamivudine - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Lamivudine - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Lamivudine - Detailed information from DrugBank.